TRDA
Entrada Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−2.49%
vs ±56.7% implied · ×0.04
shaded = implied · ▲▼ = realized
No thesis.
Linked news
NewsEntrada Therapeutics, Inc.
4.53
+0.13 · +2.88%
post 4.53 0.00%
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Baker Bros. AdvisorsBaker Bros. | $37.3M | 17.43% | 0.00% | |
| 2 | 5AM Venture Management5AM Venture | $29.9M | 13.94% | 0.00% | |
| 3 | BlackRockBlackRockindex-like | $19.0M | 8.88% | +9.52% | |
| 4 | MerckMerck | $12.8M | 5.98% | new | |
| 5 | Vanguard Capital ManagementVanguardindex-like | $9.3M | 4.36% | +1.08% | |
| 6 | MPM Oncology Impact ManagementMPM Oncology Impact | $9.2M | 4.30% | new | |
| 7 | TCG Crossover ManagementTCG Crossover | $7.8M | 3.64% | −53.65% | |
| 8 | Wellington Management GroupWellington | $7.0M | 3.28% | −7.77% | |
| 9 | Millennium ManagementMillennium | $5.6M | 2.62% | +47.10% | |
| 10 | StepStone GroupStepStone | $5.6M | 2.62% | 0.00% | |
| 11 | Geode Capital ManagementGeodeindex-like | $5.3M | 2.47% | +7.50% | |
| 12 | AQR Capital ManagementAQR | $5.1M | 2.40% | +780.00% | |
| 13 | State StreetState Streetindex-like | $4.4M | 2.05% | +11.78% | |
| 14 | T. Rowe Price AssociatesT. Rowe Price | $4.0M | 1.86% | +3.09% | |
| 15 | JPMorgan ChaseJPMorgan Chase | $3.8M | 1.79% | +3243.82% | |
| 16 | Acadian Asset ManagementAcadian | $3.0M | 1.38% | +20.32% | |
| 17 | Citadel AdvisorsCitadel | $2.9M | 1.35% | +83.39% | |
| 18 | Dimensional Fund AdvisorsDimensional | $2.8M | 1.29% | +15.92% | |
| 19 | Northern TrustNorthern Trustindex-like | $2.3M | 1.06% | +31.89% | |
| 20 | Jacobs Levy Equity ManagementJacobs Levy Equity | $2.2M | 1.04% | −9.12% | |
| 21 | Nantahala Capital ManagementNantahala | $2.2M | 1.03% | +88.65% | |
| 22 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $1.9M | 0.87% | +15.25% | |
| 23 | Charles Schwab Investment ManagementCharles Schwabindex-like | $1.5M | 0.68% | −8.20% | |
| 24 | Longaeva PartnersLongaeva Partners | $1.4M | 0.67% | −4.75% | |
| 25 | Morgan StanleyMorgan Stanley | $1.4M | 0.66% | +8.81% |
128 managers report $214.2M of Entrada Therapeutics on form 13F for the quarter ended Jun 30 '26. 17 of them hold 80% of it; Baker Bros. is largest at 17.43%.
Expected move
No implied move.
No implied move.
No implied move.